|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/06/20 Anavex Life Sciences Corp. 10-Q 12/31/19 36:1.9M Electro Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 259K
2: EX-10.1 Material Contract HTML 25K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 16K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 16K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
35: R1 Document and Entity Information HTML 45K
21: R2 Interim Condensed Consolidated Balance Sheets HTML 53K
(Unaudited)
16: R3 Interim Condensed Consolidated Balance Sheets HTML 27K
(Unaudited) (Parenthetical)
27: R4 Interim Condensed Consolidated Statements of HTML 54K
Operations (Unaudited)
34: R5 Interim Condensed Consolidated Statements of Cash HTML 51K
Flows (Unaudited)
20: R6 Interim Condensed Consolidated Statement of HTML 50K
Changes in Stockholders' Equity
15: R7 Business Description and Basis of Presentation HTML 34K
26: R8 Recent Accounting Pronouncements HTML 20K
36: R9 Other Income HTML 18K
24: R10 Equity Offering Agreements HTML 27K
33: R11 Commitments HTML 61K
19: R12 Recent Accounting Pronouncements (Policies) HTML 19K
14: R13 Commitments (Tables) HTML 58K
23: R14 Business Description and Basis of Presentation HTML 18K
(Details Narrative)
32: R15 Other Income (Details Narrative) HTML 20K
17: R16 Equity Offering Agreements (Details Narrative) HTML 49K
13: R17 Commitments (Details) HTML 35K
25: R18 Commitments (Details 1) HTML 23K
31: R19 Commitments (Details 2) HTML 48K
22: R20 Commitments (Details 3) HTML 18K
12: R21 Commitments (Details 4) HTML 24K
29: R22 Commitments (Details Narrative) HTML 31K
30: XML IDEA XML File -- Filing Summary XML 55K
28: EXCEL IDEA Workbook of Financial Reports XLSX 31K
6: EX-101.INS XBRL Instance -- avxl-20191231 XML 362K
8: EX-101.CAL XBRL Calculations -- avxl-20191231_cal XML 65K
9: EX-101.DEF XBRL Definitions -- avxl-20191231_def XML 172K
10: EX-101.LAB XBRL Labels -- avxl-20191231_lab XML 414K
11: EX-101.PRE XBRL Presentations -- avxl-20191231_pre XML 282K
7: EX-101.SCH XBRL Schema -- avxl-20191231 XSD 69K
18: ZIP XBRL Zipped Folder -- 0001731122-20-000103-xbrl Zip 49K
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Anavex Life Sciences Corp. (the “Company”) on Form 10-Q for the three months ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: February 6, 2020 | /s/Christopher Missling, PhD |
| Christopher Missling, PhD | |
| Chief Executive Officer, President, Secretary | |
|
(Principal Executive Officer)
| |
| /s/Sandra Boenisch | |
| Sandra Boenisch, CPA, CGA | |
| Principal Financial Officer, Treasurer | |
| (Principal Financial and Accounting Officer) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging,
or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required
by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/6/20 | None on these Dates | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/27/23 Anavex Life Sciences Corp. 10-K 9/30/23 54:5.7M Electro Filings LLC/FA 1/27/23 Anavex Life Sciences Corp. 10-K/A 9/30/22 4:308K Electro Filings LLC/FA 11/28/22 Anavex Life Sciences Corp. 10-K 9/30/22 49:5.1M Electro Filings LLC/FA 11/24/21 Anavex Life Sciences Corp. 10-K 9/30/21 50:13M Electro Filings LLC/FA 12/28/20 Anavex Life Sciences Corp. 10-K 9/30/20 44:3.6M Electro Filings LLC/FA |